Scientists have identified a key molecular regulator of cardiac hypertrophy (enlargement of the heart) that may provide a therapeutic target for a major risk factor of heart failure and early death. The researchers report in an upcoming edition of Nature Medicine that over-expression of the protein CIB1 (also called calmyrin) triggers biochemical processes that lead to cardiac hypertrophy. This includes activating the enzyme calcineurin, a key biochemical component in the normal development and function of heart cells. The study was posted online July 18 in advance of publication.
